The Swiss Society of Nephrology (SGN) advocates targeted screening for defined risk groups. However, given the prevalence of chronic kidney disease (CKD) in primary care, it is hardly possible to refer everyone affected to a nephrologist. Clear risk stratification is therefore essential. Drug therapy is based on several pillars and aims to slow down the rate of progression of GFR decline on the one hand and to reduce the cardiovascular risk on the other.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Across All Types of Cancer
Four-Legged Medical Assistants – Therapy Dogs in Clinical Settings
- Obesity: More than half of those affected have fatty liver disease
From screening to multimodal intervention with GLP-1-RA or resmetirom
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Preclinical Study on a Special Ginkgo biloba Extract
What role do proanthocyanidins play?
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Plastic surgery and reconstructive microsurgery for DFS